FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHH tumors. Patients and Methods: We combined transcriptome and DNA copy-number analyses for 64 primary medulloblastomas. Bioinformatic tools were used to discover marker genes of molecular variants. Differentially expressed transcripts were evaluated for prognostic value in the screening cohort. The prognostic power of follistatin-like 5 (FSTL5) immunopositivity was tested for 235 nonoverlapping medulloblastoma samples on two independent tissue microarrays. Results: Comprehensive analyses of transcriptomic and genetic alterations delineate four distinct variants of medulloblastoma. Stable subgroup separation was achieved by using the 300 transcripts that varied the most. Distinct expression patterns of FSTL5 in each molecular subgroup were confirmed by quantitative real-time polymerase chain reaction. Immunopositivity of FSTL5 identified a large cohort of patients (84 of 235 patients; 36%) at high risk for relapse and death. Importantly, more than 50% of non-WNT/non-SHH tumors displayed FSTL5 negativity, delineating a large patient cohort with a good prognosis who would otherwise be considered intermediate or high-risk on the basis of current molecular subgrouping. Conclusion: FSTL5 expression denoted a dismal prognosis both within and across medulloblastoma subgroups. The addition of FSTL5 immunohistochemistry to existing molecular stratification schemes constitutes a reliable and cost-effective tool for prognostication in future clinical trials of medulloblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Missing Value Estimation Methods for DNA Microarrays
Troyanskaya, O., Cantor, M., Sherlock, G., Brown, P., Hastie, T., Tibshirani, R., Botstein, D., & Altman, R. B. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.6.520 · Cited by 4,230
Metagenes and molecular pattern discovery using matrix factorization
Brunet, J.-P., Tamayo, P., Golub, T. R., & Mesirov, J. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308531101 · Cited by 2,183
Gajjar, A., Hernan, R., Kocak, M., Fuller, C., Lee, Y., McKinnon, P. J., Wallace, D., Lau, C., Chintagumpala, M., Ashley, D. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.032 · Cited by 279
Cited by
Molecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936
“However, the distribution of cases across the subgroups is very different in adults as compared to children [2, 28, 37, 38].”
BackgroundInfluentialSelf-citationKool, M., Korshunov, A., Remke, M., Jones, D. T. W., Schlanstein, M., Northcott, P. A., Cho, Y.-J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0958-8 · Cited by 1,056
Self-citationSubgroup-specific structural variation across 1,000 medulloblastoma genomes
Northcott, P. A., Shih, D. J. H., Peacock, J., Garzia, L., Sorana Morrissy, A., Zichner, T., Stütz, A. M., Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012) · Nature · doi:10.1038/nature11327 · Cited by 899
Self-citationRausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865
Self-citationMedulloblastomics: the end of the beginning
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y.-J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3410 · Cited by 663
Self-citationRisk stratification of childhood medulloblastoma in the molecular era: the current consensus
Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S. C., Doz, F., Kool, M., Dufour, C., Vassal, G., Milde, T., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1569-6 · Cited by 654
Self-citationSubgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma
Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D. J. H., Martin, D. C., Castelo-Branco, P., Baskin, B., Ray, P. N., Bouffet, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5052 · Cited by 485
Self-citationThe eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation
Leprivier, G., Remke, M., Rotblat, B., Dubuc, A., Mateo, A.-R. F., Kool, M., Agnihotri, S., El-Naggar, A., Yu, B., Prakash Somasekharan, S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.055 · Cited by 414
Self-citationRecurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis
Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y.-J., Shih, D. J., Luu, B., Dubuc, A. M., Northcott, P. A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70449-2 · Cited by 394
Self-citationThe clinical implications of medulloblastoma subgroups
Northcott, P. A., Korshunov, A., Pfister, S. M., & Taylor, M. D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.78 · Cited by 328
Self-citationCytogenetic Prognostication Within Medulloblastoma Subgroups
Shih, D. J. H., Northcott, P. A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., Yao, Y., Wang, X., Dubuc, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9539 · Cited by 313
Self-citationHistone deacetylase 10 promotes autophagy-mediated cell survival
Oehme, I., Linke, J.-P., Böck, B. C., Milde, T., Lodrini, M., Hartenstein, B., Wiegand, I., Eckert, C., Roth, W., Kool, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300113110 · Cited by 221
“HDAC10 expression in other highly malignant pediatric tumors of the nervous system, such as medulloblastoma [Heidelberg cohort (33); GEO accession no.”
BackgroundSelf-citationTERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
Remke, M., Ramaswamy, V., Peacock, J., Shih, D. J. H., Koelsche, C., Northcott, P. A., Hill, N., Cavalli, F. M. G., Kool, M., Wang, X., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1198-2 · Cited by 164
Self-citation
Metadata
- Authors
- Remke, M., Hielscher, T., Korshunov, A., Northcott, P. A., Bender, S., Kool, M., Westermann, F., Benner, A., Cin, H., Ryzhova, M., Sturm, D., Witt, H., Haag, D., Toedt, G., Wittmann, A., Schöttler, A., von Bueren, A. O., von Deimling, A., Rutkowski, S., Scheurlen, W., Kulozik, A. E., Taylor, M. D., Lichter, P., & Pfister, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-10-10
- Volume
- 29
- Issue
- 29
- Pages
- 3852-3861
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141444430
- Cited by
- 155
- References
- 3
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.